Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2024
Institutional positions in Inhibrx Biosciences, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- +6 vs. Q3 2024
- Shares held
- 11.2M
- +2.29M (+25.8%) vs. Q3 2024
- Total value
- $171.9M
- +$32.9M (+23.7%) vs. Q3 2024
- New holders
- 17
- 31 more added
- Sold out
- 11
- 29 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 162 | $1.36B |
| Q1 2026 | 135 | $854.6M |
| Q4 2025 | 138 | $1.01B |
| Q3 2025 | 102 | $353.6M |
| Q2 2025 | 89 | $148.9M |
| Q1 2025 | 92 | $151.0M |
| Q4 2024 | 101 | $171.9M |
| Q3 2024 | 96 | $139.3M |
| Q2 2024 | 88 | $137.9M |
| Q1 2024 | 126 | $1.34B |
| Q4 2023 | 126 | $1.54B |
| Q3 2023 | 111 | $716.1M |
| Q2 2023 | 107 | $935.2M |
| Q1 2023 | 108 | $691.6M |
| Q4 2022 | 116 | $886.0M |
| Q3 2022 | 102 | $512.2M |
| Q2 2022 | 100 | $297.3M |
| Q1 2022 | 99 | $548.0M |
| Q4 2021 | 101 | $1.01B |
| Q3 2021 | 66 | $681.6M |
| Q2 2021 | 61 | $538.8M |
| Q1 2021 | 55 | $326.3M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Inhibrx Biosciences, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Viking Global Investors LPSuperinvestorViking Global Investors | 1,787,705 | $27.5M | 0.09% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −25,100−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −21,066−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −20,469−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −13,012−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −10,952−100.0% | Sold out |
| Erste Asset Management GmbH | 0 | $0 | 0.00% | −2,175−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −1,666−100.0% | Sold out |
| Larson Financial Group LLC | 0 | $0 | 0.00% | −581−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −61−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Bluefin Capital Management, LLC | – | – | – | – | Not filed |